Therapeutic approaches to drug targets in atherosclerosis

Saudi Pharmaceutical Journal

Volumn 22, Issue 3, 2014, Pages 179-190

  Jamkhande, Prasad G ^a   Chandak, Prakash G ^a   Dhawale, Shashikant C ^a   Barde, Sonal R ^a   Tidke, Priti S ^b   Sakhare, Ram S ^c  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

^b R C PATEL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH   (India)

^c Indira College of Pharmacy   (India)

Author keywords

Atherosclerosis; Drug targets; Endoglin; Heat shock protein; Hyperlipidemia

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN VACCINE; CYTOCHROME P450; DIACYLGLYCEROLACYLTRANSFERASE INHIBITOR; ENDOGLIN; ENDOGLIN RECEPTOR; ENZYME INHIBITOR; HEAT SHOCK PROTEIN 65; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; LANOSTEROL SYNTHASE INHIBITOR; NITRIC OXIDE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOLIPASE A2 INHIBITOR; SCAVENGER RECEPTOR; SQUALENE SYNTHASE INHIBITOR; THYROID HORMONE DERIVATIVE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD CLOTTING; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; HUMAN; HYPERTENSION; REVIEW; RISK FACTOR; SMOKING;

EID: 84904048489     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsps.2013.04.005     Document Type: Review

References (67)

1. Agnes Boullier, David A.B., Mi-Kyung Chang., Edward A.D., Peter Friedman, Kristin Gillotte-Taylor, Sohvi Hörkkö, Wulf Palinski, Oswald Quehenberger, Peter Shaw, Daniel Steinberg, valeska Terpstra Scavenger Receptors, Oxidized LDL, and Atherosclerosis 2005, Annals New York Academy of Sciences, 214-224.
2. Alexander P.R., Arnold Kahn, Brain H.E., Mark J.P., Natalia Sadetsky, Dale Williams O., Joseph F.P., David R.J., Marshall L.S. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. The Journal of Urology 2011, 185:920-925.
3. Amala P.C., Akiko Maehara, Gary S.M., Roxana Mehran, Sunil Kanwal, Ahmed Hassanin, Diaa Hakim, Ning Guo, Usman Baber, Robert Pyo, Jeffrey W.M., Martin Fahy, Jason C.K., George D.D. High platelet reactivity on clopidrogrel therapy correlates with increases coronary atherosclerosis and calcification. JACC: Cardiovascular Imaging 2012, 5:540-549.
4. Andrea H.R., Carmen A.A., Jane Y.E., Cynthia G.S., Olivier H., Morand, Robert A.H., Murray W.H. Enhanced synthesis of the oxysterol 24(s), 25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation. Circulation Research 2003, 93:717-725.
5. Anthony Colpo LDL cholesterol: "bad" cholesterol, or bad science?. Journal of American Physicians and Surgeons. 2005, 10(3):83-89.
6. Anthony J.Y., John D.D., Kimberly A.B., Patrick Y.Lee. Adventitial dysfunction: an evolutionary model for understanding atherosclerosis. Medical Hypotheses 2005, 65:962-965.
7. Barbara M.M., Marian U.C., Alan J.G., Fiona Mitchell, Hema Navaratnam, Rosemary O.H., Psych D., Peter C.E., Michael R., Le Grande Lifestyle and physiological risk factor profiles six weeks after an acute cardiac event: are patients achieving recommended targets for secondary prevention?. Heart, Lung and Circulation 2011, 20:446-451.
8. Bei Zhang B., Zhou Gaochao, Li Cai AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metabolism 2009, 9:407-416.
9. Bradford B.W., Thomas J.D. The genetics of cerebrovascular atherosclerosis. Seminars in Cerebrovascular Diseases and Stroke 2002, 2:13-14.
10. Wong Brian.W., Meredith Anna., Lin David., McManus Bruce.M. The biological role of inflammation in atherosclerosis. Canadial Journal of Cardiology 2012, 28(6):631-641.
11. Chandak P.G., Obrowsky S., Radovic B., Doddapattar P., Aflaki E., Kratzer A., Doshi L.S., Povoden S., Ahammer H., Hoefler G., Levak-Frank S., Kratky D. Lack of acyl CoA: diacylglycerolacyltransferase 1 reduces intestinal cholesterol absorption and attenuates atherosclerosis in apolipoprotein E knockout mice. Biochimica et Biophysica Acta 2011, 1811(12):1011-1020.
12. Claudio Napoli, Ignarro Louis J. Nitric oxide and atherosclerosis. Nitric Oxide 2001, 5(2):88-97.
13. Claudio Napoli, Filomena de Nigris, Sharon Williams-lgnarro, Vincenzo Sica, Ignarro Louis J. Nitric oxide and atherosclerosis: an update. Journal of Nitric Oxide 2006, 15(4):265-279.
14. David Spence J. Intensive management of risk factors for accelerated atherosclerosis: the role of multiple interventions. Current Neurology and Neuroscience Reports. 2007, 7:42-48.
15. Elstad M.R., La Pine T.R., Cowley F.S., Mc Ever R.P. P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. Journal of Immunology 1995, 155:2109-2122.
16. Eugene Morkin, Paul Ladenson, Steven Goldman, Cynthia Adamson Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. Journal of Molecular and Cellular Cardiology. 2004, 37:1137-1146.
17. Eva Lonn Lipoprotein-associated phospholipase A2: a new therapeutic target. Canadian Journal of Cardiology 2010, 26:27A-37A.
18. Francoise Chiche, Christel Jublanc, Mathieu Coudert, Valérie Carreau, Jean-Francois Kahn, Eric Bruckert Hypothyroidism is not associated with increased carotid atherosclerosis when cardiovascular risk factors are accounted for in hyperlipidemic patients. Atherosclerosis 2009, 203:269-276.
19. Francisco J.B., Carmelo Bernabéu Alternative splicing in endothelial senescence: role of the TGF-ß co-receptor endoglin. Senescence 2012, 203:953-978.
20. Gerrity R.G., Antonoy A.S. The pathogenesis of atherosclerosis. Diabetologia 1997, 40:S108-S110.
21. Pikuleva Irina A. Cholesterol-metabolizing cytochromes P450. Drug Metabolism and Disposition 2006, 34(4):513-520.
22. James B.M., Brian K.C. Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role?. FEMS Microbiology Letters 2001, 197:1-9.
23. Jeffrey A.R., Richard Sulsky, Chong-Qing Sun, Ligaya M.S., Tammy Wang, John K.D., Ying Chen, David R.M., Prakash Taunk, William A.S., Scott A.B., Shih-Jung Lan, Fergal Connolly, Lori K.K., Talal Sabrah, Haris Jamil, David Gordon, Thomas W.H., John R.W. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. Journal of Medicinal Chemistry 2001, 44(6):851-856.
24. Jerzy Beltowski. Leptin and atherosclerosis. Atherosclerosis 2006, 189:47-60.
25. John F.K. Atherosclerosis: from lesion formation to plaque activation and endothelial function. Molecular Aspects of Medicine 2000, 21:99-166.
26. John B.S. Hypertension and atherosclerosis: clinical implications from the ALLHAT trial. Current Atherosclerosis Reports 2005, 7:132-139.
27. John R.W., Richard E.G., Thomas W.H., Cynthia Arbeeny, Michael Cap, Fergal Connolly, Ching-Hsuen Chu, Rocco J.G., David A.G., Haris Jamil, Kern G.J., Lori K.K., Shih-Jung Lan, Thomas J.M., Beverly Ricci, Mujing Yan, Douglas Young, Ying Chen, Olga M.F., Janette V.H., Christa L.M., Michael A.P., Jeffrey A.R., Ligaya M.S., William A.S., Richard Sulsky, Prakash Taunk, David R.M., Joseph A.T., Michael Lawrence R., John K.D., Scott A.B. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998, 282:751-754.
28. John M.Chapman, Jan S.Redfern, Mark E.McGovern, Philippe Giral Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 2010, 126:314-345.
29. Rubin Jonathan., Nambi Vijay., Lloyd E.C., Michael W.S., Stephen P.J., Josef Coresh A., Sharrett Richey., Selvin Elizabeth. Hyperglycemia and arterial stiffness: the atherosclerosis risk in the communities study. Atherosclerosis 2012, 225(1):246-251.
30. Kathryn J.M., Mason W.Freeman. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arteriosclerosis Thrombosis Vascular Biology 2006, 26:1702-1711.
31. Kathryn D.L., Jennifer T.M., Nicholas W.W., Annette Wyrick, Toni Voelker, Deborah J.H. DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning, and expression in insect cells of two polypeptides from mortierella ramanniana with Diacylglycerol acyltransferase activity. The Journal of Biological Chemistry 2001, 276:38862-38869.
32. Keith Suckling Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis 2010, 212:357-366.
33. Kristina Schoonjans, Bart Staels, Johan Auwerx Role of the peroxisome proliferator-activated Receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Journalof Lipid Research 1996, 37:907-925.
34. Li A.C., Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nature Medicine 2002, 8:1235-1242.
35. Long Juna, Lin Jie, Yuan Dongping, Yang Xin, Li Taiming, Cao Rongyue, Wu Jie, Liu Jingjing Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis. Vaccine 2012, 30:1029-1037.
36. Margaret Chan Burden: mortality, morbidity and risk factors. Global Status Report On Noncommunicable Diseases 2010.
37. Markus Juonalab, Mika Kähönen, Risto Huupponen, Jorma S.A.Viikari, Olli T.Raitakari Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in young finns study. Atherosclerosis 2012, 223:497-503.
38. Mervi Oikonen, Maria Wendelin-Saarenhovi, Leo-Pekka Lyytikäinen, Niina Siitonen, Britt-Marie Loo, Antti Jula, Ilkka Seppälä, Liisa Saarikoski, Terho Lehtimäki, Nina Hutri-Kähönen, Mohammed Al-Omran Atherosclerotic disease and risk factor modification in Saudi Arabia: a call to action. Journal of Vascular Health and Risk Management 2012, 8:349-355.
39. Pablo Piñón, Juan C.K. Inflammation, atherosclerosis, and cardiovascular diseaserisk: PAPP-A, Lp-PLA2, and Cystatin C. new insights or redundant information?. Revista Española de Cardiologia 2006, 59(3):247-258.
40. Pao-Ling Torng a, Ta-Chen Su b, Fung C Sung, Kuo.-Liong Chien, Chien Su-Cheng Huang, Song.-Nan Chow, Yuan.-Teh.Lee Effects of menopause on intraindividual changes in serum lipids, blood pressure, and body weight- the Chin-Shan community cardiovascular cohort study. Atherosclerosis 2002, 161:409-415.
41. Paolo Puddu, Giovanni MPuddu, Luciana Basagli, Giorgio Massarelli, Antonio Muscari Coronary and cerebrovascular atherosclerosis: two aspects of the same disease or two different pathologies?. Archives of Gerontology and Geriatrics 1995, 20:5-22.
42. Paul Holvoet, Desire Collen Oxidation of low density lipoproteins in the pathogenesis of Atherosclerosis. Atherosclerosis 1998, 137:S33-S38.
43. Paul J.D., Faith B.D. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002, 12(6):459-466.
44. Peter ten Dijke, Marie-Jose Goumans, Evangelia Pardali Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008, 11:79-89.
45. Petr Nachtigal, Lenka Zemankova, Jana Rathous, Zbynek Strasky The role of endoglin in atherosclerosis. Atherosclerosis 2012, 224:4-11.
46. Philip J.Barter, John J.P.Kastelein Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. Journal of the American College of Cardiology 2006, 47(3):492-499.
47. Pieter A.D., Wouter Jukemab, Wilko Spiering, Joep C.D., Kastelein John J.P. Molecular genetics and gene expression in atherosclerosis. International Journal of Cardiology 2001, 80:161-172.
48. Qi Wei, Doris a Peter A., Martin V.P., Boerwinkle Eric, Jacobs David R., Siscovick David S., Fornage Myriam Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: Interaction with cigarette smoking. Atherosclerosis 2007, 190:26-34.
49. Qian Wang, Xuedong Zhou, Dingming Huang Role for porphyromonasgingivalis in the progression of atherosclerosis. Medical Hypotheses 2009, 72:71-73.
50. Robert S.R. HDL-C and diabetic patient: target for therapeutic intervention. Diabetes Research and Clinical Practice 2005, 68S2:S36-S42.
51. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
52. Ross R., Glomset J., Harker L. Response to injury and atherogenesis. TheAmerican Journal of Pathophysiology 1977, 86:675-684.
53. Russo Guilia, Jane A.Leopold., Joseph Loscalzo Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascular Pharmacology 2002, 38(5):259-269.
54. Sagar P.M., Rekha D.K., Menaa Farid., Sachin L.B. Therapeutic approaches to drug targets in hyperlipidemia. Biomedicine. 2012, 2(4):137-146.
55. Sainani, Gs., Talwalkar, Pg., Wadia, Rs., Keshvani, A.A., (2008) Hyperhomocysteinemia and its implications in atherosclerosis the Indian Scenario. Medicine, update. 12-20.
56. Sandra N.V., Frank L.J.Visseren Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis 2011, 214:3-10.
57. Sarah Song, Bruce Ovbiagele Management of risk factors for accelerated atherosclerosis. Current Treatment Options in Neurology 2009, 11:460-472.
58. Steve E.H., Laleh M. Genetic risk factors for stroke and carotidatherosclerosis: insights into pathophysiologyfrom candidate gene approaches. Lancet Neurology 2004, 3:227-236.
59. Stuart B.R., Tram Huynh, Adriano Afonso, Harry R.D., Nathan Yumibe, John W.C., Duane A.B. Discovery of 1-(4 Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) 2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. Journal of Medicinal Chemistry 1998, 41(6):973-980.
60. Tohru Ugawa, Hirotoshi Kakuta, Hiroshi Moritani, Osamu Inagaki Effect of YM-53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamsters. British Journal of Pharmacology 2002, 137:561-567.
61. Toshihiro Ichiki Thyroid hormone and atherosclerosis. Vascular Pharmacology 2010, 52:151-156.
62. Valentin S.Z., Nils H.S. Monitoring of atherosclerosis. International Journal of Cardiology 2004, 95:39-42.
63. Vasilios G.Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Dimitri P.Mikhailidis Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. The Open Cardiovascular Medicine Journal 2011, 5:24-34.
64. Wen-Harn Pan, Benjam Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan - a unique experience. Atherosclerosis 1995, 118:285-295.
65. Weyrich A.S., McIntyre T.M., McEver R.P., Prescott S.M., Zimmerman G.A. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. Journal of Clinical Investigation 1995, 95:2297-2303.
66. Wilensky R.L., Hamamdzic D. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Current Opinion in Cardiology 2007, 22:545-551.
67. Williams K.J., Tabas I. The response-to-retention hypothesis of early atherogenesis. Atherosclerosis, Thrombosis, and Vascular Biology 1995, 15:551-561.